Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy

Developmental Medicine and Child Neurology

Volumn 49, Issue 1, 2007, Pages 56-61

  Desloovere, Kaat ^a   Molenaers, Guy ^b   De Cat, Jos ^b   Pauwels, Petra ^b   Van Campenhout, Anja ^b   Ortibus, Els ^b   Fabry, Guy ^b   De Cock, Paul ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; CASE CONTROL STUDY; CEREBRAL PALSY; CHILD; CLASSIFICATION; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAIT; HEMIPLEGIA; HIP; HUMAN; JOINT FUNCTION; KNEE; MALE; MOTOR DEVELOPMENT; MOTOR PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SPASTICITY; DRUG EFFECT; HOSPITALIZATION; PATHOPHYSIOLOGY; ROTATION;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; FEMALE; GAIT; HEMIPLEGIA; HIP; HUMANS; MALE; MOTOR SKILLS; NEUROMUSCULAR AGENTS; ROTATION; SEVERITY OF ILLNESS INDEX;

EID: 33847059272     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S001216220700014X.x     Document Type: Article

References (24)

1. Dabney KW, Lipton GE, Miller F. (1997) Cerebral palsy. Pediatrics 9: 81-88.
2. Bleck E. (1987). Goals, treatment and management. In: Bleck E, editor. Orthopaedic Management in Cerebral Palsy. Clinics in Developmental Medicine No. 99/100. London: Mac Keith Press. p 142-212.
3. Gage JR. (2004) An overview of treatment. In: Gage JR, editor. The Treatment of Gait Problems in Cerebral Palsy. Clinics in Developmental Medicine No. 164/165. London: Mac Keith Press. p 180-204.
4. Molenaers G, Desloovere K, Eyssen M, De Cat J, Jonkers I, De Cock P. (1999) Botulinum toxin type A treatment of cerebral palsy: An integrated approach. Eur J Neurol 6: S51-S57.
5. Graham HK. (2001) Botulinum toxin type A management of spasticity in the context of orthopedic surgery for children with spastic cerebral palsy. Eur J Neurol 8: 30-39.
6. Brown GT, Burns SA. (2001) The efficacy of neurodevelopmental treatment in paediatrics: A systematic review. Br J Occup Ther 64: 235-244.
7. Dodd KJ, Taylor NF, Graham HK. (2003) A randomized clinical trial of strength training in young people with cerebral palsy. Dev Med Child Neurol 45: 652-657.
8. Trahan J, Malouin F. (2004) Intermittent intensive physiotherapy in children with cerebral palsy: A pilot study. Dev Med Child Neurol 44: 233-239.
9. Graham HK, Aoki KR, Autti-Rämo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, et al. (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67-79.
10. Koman LA, Smith BP, Tingey CT, Mooney JF, Slone S, Naughton MJ. (1999) The effect of botulinum toxin type A injections on the natural history of equinus foot deformity in pediatric cerebral palsy patients. Eur J Neurol 6: S19-S22.
11. Bakheit AMO, Severa S, Cosgrove A, Morton R, Rousso SH, Doederlein L, Lin J-P. (2001) Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43: 234-238.
12. Borton D, Walker K, Pirpiris M, Nattrass G, Graham HK. (2001) Isolated calf lengthening in cerebral palsy-outcome: Analysis of risk factors. J Bone Joint Surg (Br) 83: 364-370.
13. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P. (2001) A randomised study of botulinum toxin A and casting in the ambulant child with cerebral palsy using objective measures. Eur J Neurol 8: 75-87.
14. Gage JR. (1991) Cerebral palsy gait. In: Gage JR, editor. Gait Analysis in Cerebral Palsy. Clinics in Developmental Medicine No. 121. London: Mac Keith Press. p 101-131.
15. Perry J, editor. (1992) Gait Analysis: Normal and Pathological Function. Thorofare, NJ: Slack, Inc.
16. Boyd RN, Hays RM. (2001) Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: A systematic review. Eur J Neurol 8: 1-20.
17. Boyd RN, Starr R, Wolfe R, Graham HK. (2000) Biomechanical transformation of the gastrocsoleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 42: 32-41.
18. Koman LA, Mooney JF III, Smith BP, Walker F, Leon JM, and the Botox Study Group. (2000) Botulinum toxin A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomised, double blind, placebo-controlled trial. J Pediatr Orthop 20: 108-115.
19. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Carr L, MacLean J, Lin J-P, Lynch B, Theologis T, Wendorff J, et al. (2002) Botulinum toxin for treatment of spasticity in diplegic cerebral palsy: a randomised, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 44: 666-675.
20. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ. (2001) The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: A randomised controlled trial. Eur J Neurol 8: 50-58.
21. Reddihough DS, King JA, Coleman GJ, Fosang A, McCoy AT, Thomason P, Graham HK. (2002) Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44: 820-827.
22. Galli M, Crivellini M, Santambrogio GC, Fazzi E, Motta F. (2001) Short-term effects of 'botulinum toxin A' as treatment for children with cerebral palsy: Kinematic and kinetic aspects at the ankle joint. Funct Neurol 16: 317-323.
23. Molenaers G, Desloovere K, De Cat J, Jonkers I, De Borre L, Pauwels P, Nijs J, Fabry G, De Cock P. (2001) Single event multilevel BTX-A treatment and surgery: Similarities and differences. Eur J Neurol 8: 88-97.
24. Polak F, Morton R, Ward C, Wallace WA, Döderlein L, Siebel A. (2002) Double-blind comparison study of two doses of botulinum toxin A injected into the calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 44: 551-555.